The role of mutations in epigenetic regulators in myeloid malignancies

Immunological Reviews

Volumn 263, Issue 1, 2015, Pages 22-35

  Woods, Brittany A ^a,b   Levine, Ross L ^a,b  

^a Gerstner Sloan Kettering Graduate School of Biomedical Sciences   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chromatin regulation; Genomics; Myelopoiesis

Indexed keywords

ADDITIONAL SEX COMBS LIKE 1; CD135 ANTIGEN; COHESIN; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; NUCLEOPHOSMIN; PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOGENETICS; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENOME IMPRINTING; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HETEROZYGOSITY; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA REMISSION; MISSENSE MUTATION; MYELODYSPLASTIC SYNDROME; MYELOPOIESIS; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SOMATIC MUTATION; SPLICEOSOME; TRANSCRIPTION ELONGATION; ANIMAL; GENETIC EPIGENESIS; GENETICS; HEMATOPOIETIC STEM CELL; MUTATION; MYELOID LEUKEMIA; PHYSIOLOGY;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID; MUTATION;

EID: 84930343240     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12246     Document Type: Article

References (143)

1. Byrd JC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-4336.
2. Schlenk RF, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-1918.
3. Patel JP, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366:1079-1089.
4. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012;12:599-612.
5. Gilliland DG. Hematologic malignancies. Curr Opin Hematol 2001;8:189-191.
6. Mikkelsen TS, et al. Dissecting direct reprogramming through integrative genomic analysis. Nature 2008;454:49-55.
7. Cedar H, Bergman Y. Epigenetics of haematopoietic cell development. Nat Rev Immunol 2011;11:478-488.
8. Conway O'Brien E, Prideaux S, Chevassut T. The epigenetic landscape of acute myeloid leukemia. Adv Hematol 2014;2014:103175.
9. Super HJ, et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA- topoisomerase II. Blood 1993;82:3705-3711.
10. Thirman MJ, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 1993;329:909-914.
11. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007;7:823-833.
12. Viny AD, Levine RL. Genetics of myeloproliferative neoplasms. Cancer J 2014;20:61-65.
13. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008;9:465-476.
14. Ji H, et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 2010;467:338-342.
15. Borgel J, et al. Targets and dynamics of promoter DNA methylation during early mouse development. Nat Genet 2010;42:1093-1100.
16. Faber J, et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009;113:2375-2385.
17. Pérez C, et al. Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. Haematologica 2013;98:1414-1420.
18. Figueroa ME, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010;17:13-27.
19. Ley TJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010;363:2424-2433.
20. Thol F, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011;29:2889-2896.
21. Gowher H, et al. Mutational analysis of the catalytic domain of the murine Dnmt3a DNA-(cytosine C5)-methyltransferase. J Mol Biol 2006;357:928-941.
22. Yamashita Y, et al. Array-based genomic resequencing of human leukemia. Oncogene 2010;29:3723-3731.
23. Kim SJ, Zhao H, Hardikar S, Singh AK, Goodell MA, Chen T. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood 2013;122:4086-4089.
24. Russler-Germain DA, et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 2014;25:442-454.
25. Tadokoro Y, Ema H, Okano M, Li E, Nakauchi H. De novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells. J Exp Med 2007;204:715-722.
26. Challen GA, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2012;44:23-31.
27. Verdoni AM, Cole CB, Klco JM, Ley TJ. DNMT3A R882H overexpression leads to hematopoietic and skin alterations in transgenic mice. Blood 2013;122:479.
28. Xu J, et al. DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells. Proc Natl Acad Sci USA 2014;111:2620-2625.
29. Fernandez HF, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249-1259.
30. Abdel-Wahab O, Pardanani A, Rampal R, Lasho TL, Levine RL, Tefferi A. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 2011;25:1219-1220.
31. Stegelmann F, et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 2011;25:1217-1219.
32. Walter MJ, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011;25:1153-1158.
33. Fried I, et al. Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia. Haematologica 2012;97:246-250.
34. Shlush LI, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014;506:328-333.
35. Tahiliani M, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009;324:930-935.
36. Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H, Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res 2002;62:4075-4080.
37. He Y-F, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011;333:1303-1307.
38. Wu H, et al. Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Genes Dev 2011;25:679-684.
39. Shen L, et al. Genome-wide analysis reveals TET- and TDG-dependent 5-methylcytosine oxidation dynamics. Cell 2013;153:692-706.
40. Delhommeau F, et al. Mutation in TET2 in Myeloid Cancers. N Engl J Med 2009;360:2289-2301.
41. Langemeijer SMC, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009;41:838-842.
42. Abdel-Wahab O, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009;114:144-147.
43. Tefferi A, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009;23:1343-1345.
44. Kosmider O, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009;94:1676-1681.
45. Metzeler KH, et al. TET2 mutations improve the new European Leukemia: Net risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011;29:1373-1381.
46. Bejar R, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-2506.
47. Smith AE, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010;116:3923-3932.
48. Ko M, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010;468:839-843.
49. Moran-Crusio K, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011;20:11-24.
50. Yamazaki J, et al. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 2012;7:201-207.
51. Figueroa ME, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553-567.
52. Xu W, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011;19:17-30.
53. Yan H, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-773.
54. Mardis ER, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058-1066.
55. Marcucci G, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:2348-2355.
56. Ward PS, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:225-234.
57. Tefferi A, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012;26:475-480.
58. Dang L, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010;465:966.
59. Akalin A, et al. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet 2012;8:e1002781.
60. Sasaki M, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012;488:656-659.
61. Chowdhury R, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 2011;12:463-469.
62. Lu C, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012;483:474-478.
63. Sorensen PH, et al. Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin Invest 1994;93:429-437.
64. Cox MC, et al. Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients. Am J Clin Pathol 2004;122:298-306.
65. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011;469:343-349.
66. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323-5335.
67. Varambally S, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-629.
68. Varambally S, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008;322:1695-1699.
69. Morin RD, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010;42:181-185.
70. Sneeringer CJ, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci USA 2010;107:20980-20985.
71. Yu J, et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007;67:10657-10663.
72. Le Beau MM, Espinosa R, Davis EM, Eisenbart JD, Larson RA, Green ED. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996;88:1930-1935.
73. Guglielmelli P, et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011;118:5227-5234.
74. Ernst T, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010;42:722-726.
75. Nikoloski G, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010;42:665-667.
76. Khan SN, et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia 2013;27:1301-1309.
77. Muto T, et al. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med 2013;210:2627-2639.
78. Brecqueville M, et al. Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. Blood Cancer J 2011;1:e33.
79. Score J, et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 2012;119:1208-1213.
80. Lessard J, Schumacher A, Thorsteinsdottir U, van Lohuizen M, Magnuson T, Sauvageau G. Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation. Genes Dev 1999;13:2691-2703.
81. Herrera-Merchan A, Arranz L, Ligos JM, de Molina A, Dominguez O, Gonzalez S. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun 2012;3:623.
82. Gelsi-Boyer V, Brecqueville M, Devillier R. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol 2012;5:12.
83. Scheuermann JC, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 2010;465:243-247.
84. Abdel-Wahab O, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011;25:1200-1202.
85. Abdel-Wahab O, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012;22:180-193.
86. Schnittger S, et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 2013;27:82-91.
87. Abdel-Wahab O, et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med 2013;210:2641-2659.
88. Abdel-Wahab O, Dey A. The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics. Leukemia 2012;27:10-15.
89. Bejar R, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012;30:3376-3382.
90. Gelsi-Boyer V, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010;151:365-375.
91. Abdel-Wahab O, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010;70:447-452.
92. Abdel-Wahab O, Kilpivaara O, Patel J, Busque L, Levine RL. The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia 2010;24:1656-1657.
93. Metzeler KH, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011;118:6920-6929.
94. Losada A. Cohesin in cancer: chromosome segregation and beyond. Nat Rev Cancer 2014;14:389-393.
95. Lawrence MS, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014;505:495-501.
96. Barber TD, et al. Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc Natl Acad Sci USA 2008;105:3443-3448.
97. Solomon DA, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 2011;333:1039-1043.
98. Welch JS, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012;150:264-278.
99. Thota S, et al. Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood 2014;124:1790-1798.
100. Duijf PHG, Benezra R. The cancer biology of whole-chromosome instability. Oncogene 2013;32:4727-4736.
101. Thol F, et al. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood 2014;123:914-920.
102. Lovén J, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013;153:320-334.
103. Chapuy B, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 2013;24:777-790.
104. Visconte V, Makishima H, Maciejewski JP, Tiu RV. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia 2012;26:2447-2454.
105. Gómez Acuña LI, Fiszbein A, Alló M, Schor IE, Kornblihtt AR. Connections between chromatin signatures and splicing. Wiley Interdiscip Rev RNA 2013;4:77-91.
106. Shah MY, et al. DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Res 2010;70:5840-5850.
107. Ostler KR, et al. Truncated DNMT3B isoform DNMT3B7 Suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma. Cancer Res 2012;72:4714-4723.
108. Nangalia J, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-2405.
109. Klampfl T, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379-2390.
110. Rampal R, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014;123:e123-e133.
111. Ghoshal K, et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 2005;25:4727-4741.
112. Patel K, Dickson J, Din S, Macleod K, Jodrell D, Ramsahoye B. Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res 2010;38:4313-4324.
113. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-Aza-2′-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 2008;28:752-771.
114. Figueroa ME, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009;114:3448-3458.
115. Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 2008;45:23-30.
116. Fandy TE, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009;114:2764-2773.
117. Wong Y-F, Jakt LM, Nishikawa S-I. Prolonged treatment with DNMT inhibitors induces distinct effects in promoters and gene-bodies. PLoS ONE 2013;8:e71099.
118. Insinga A, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005;11:71-76.
119. Nakagawa M, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007;18:769-774.
120. Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 2008;45:23-30.
121. Garcia-Manero G, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111:1060-1066.
122. Garcia-Manero G, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008;112:981-989.
123. Giles F, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006;12:4628-4635.
124. Gojo I, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007;109:2781-2790.
125. Quintás-Cardama A, Santos FPS, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2011;25:226-235.
126. Fiskus W, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009;114:2733-2743.
127. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res 2005;29:739-748.
128. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-107.
129. Gore SD, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006;66:6361-6369.
130. Soriano AO, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110:2302-2308.
131. Blum W, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25:3884-3891.
132. Bernt KM, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011;20:66-78.
133. Deshpande AJ, et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood 2013;121:2533-2541.
134. Daigle SR, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011;20:53-65.
135. Daigle SR, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013;122:1017-1025.
136. Dinner SN, Giles FJ, Altman JK. New strategies for relapsed acute myeloid leukemia: fertile ground for translational research. Curr Opin Hematol 2014;21:79-86.
137. Wang F, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013;340:622-626.
138. Rohle D, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013;340:626-630.
139. Chaturvedi A, et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013;122:2877-2887.
140. Sanyal A, Lajoie BR, Jain G, Dekker J. The long-range interaction landscape of gene promoters. Nature 2012;6:109-113.
141. Dekker J, Rippe K, Dekker M, Kleckner N. Capturing chromosome conformation. Science 2002;295:1306-1311.
142. Hagège H, et al. Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nat Protoc 2007;2:1722-1733.
143. Belton J-M, McCord RP, Gibcus JH, Naumova N, Zhan Y, Dekker J. Hi-C: a comprehensive technique to capture the conformation of genomes. Methods 2012;58:268-276.